Phase I, Open-label, Three-Period Crossover Study to Investigate the Effect of a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tepotinib in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2018
Price : $35 *
At a glance
- Drugs Tepotinib (Primary) ; Omeprazole
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 16 Jul 2018 Status changed from recruiting to completed.
- 11 Jun 2018 Planned End Date changed from 3 Jul 2018 to 18 Jul 2018.
- 11 Jun 2018 Planned primary completion date changed from 3 Jul 2018 to 29 Jun 2018.